- Elaine is a chemist with 30 years’ experience in biopharmaceutical Regulatory Affairs. Elaine started her career in the industry with Almirall, S.A. (Spain). She most recently held the post of Director, Regulatory Affairs (Oncology) for Amgen. She worked in Regulatory Affairs with Cortecs, an emerging biotechnology company, Chugai, a medium size Japanese pharma firm, and was Regulatory Director of BMS in UK. She was a principal partner with Gerry McGettigan in their consultancy firm, GMG BioBusiness Ltd, where she oversaw the successful completion of a range of projects and general management of the organization, including regulatory strategy and submissions. She was integral to the acquisition negotiations for GMG BioBusiness with a major US CRO. Elaine has contributed to the successful development of small molecules and biotechnology agents in the fields of respiratory, oncology, haematology and GI diseases, amongst others. Elaine also has significant interest and experience in Emerging Markets.
- Gerry, a molecular biologist, has over 30 years' experience in the biotechnology and pharmaceutical industries, in regulatory affairs, clinical development and business development, as well as in various Non-Executive Director roles. He has worked with large and medium pharma companies (Almirall, Spain and GSK) and in 1990’s headed up the European Regulatory & Scientific Affairs function of The Liposome Company, a US biotechnology firm. With Elaine, he founded the European regulatory affairs and product development consultancy company, GMG BioBusiness Ltd, which was acquired by a top 5 CRO in 2005. He also set up and was the first CEO of the Catalan biotechnology development agency, Biocat, based in Barcelona. Gerry has worked with many EU, US and other clients on projects ranging from early-stage regulatory strategy for emerging biotechs to advising on strategy and operations for major developments of large pharma firms. Gerry has excellent relationships with top level business, science and governmental executives.